Reviewing the cost-effectiveness of endocrine early breast cancer therapies: Influence of differences in modeling methods on outcomes

Value in Health

Volumn 15, Issue 1, 2012, Pages 94-105

  Frederix, Gerardus W J ^a   Severens, Johan L ^b   Hvels, Anke M ^c   Raaijmakers, Jan A M ^c,d   Schellens, Jan H M ^a,d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c GLAXOSMITHKLINE   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

economic evaluations; endocrine therapy; Markov

Indexed keywords

ANASTROZOLE; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; EARLY CANCER; HEALTH CARE COST; HUMAN; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84856014768     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.08.003     Document Type: Article

References (58)

1. D.M. Parkin, F. Bray, J. Ferlay, P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108 (Pubitemid 40372904)
2. V. Kataja, M. Castiglione Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl. 2009 10 14
3. K.J. Dedes, K. Matter-Walstra, M. Schwenkglenks Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation Eur J Cancer 45 2009 1397 1406
4. Q.A. Le, J.W. Hay Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer Cancer 115 2009 489 498
5. H.G. Eichler, S.X. Kong, W.C. Gerth Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7 2004 518 528 (Pubitemid 39390832)
6. J. Hjelmgren, F. Berggren, F. Andersson Health economic guidelines - similarities, differences and some implications Value Health 4 2001 225 250 (Pubitemid 32661267)
7. J. Karnon Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness Pharmacoeconomics 24 2006 215 232 (Pubitemid 43374374)
8. T. Younis, D. Rayson, R. Dewar, C. Skedgel Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer Ann Oncol 18 2007 293 298 (Pubitemid 46323096)
9. L. Annemans Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making Pharmacoeconomics 26 2008 409 423 (Pubitemid 351572053)
10. Tamoxifen for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group Lancet 351 1998 1451 1467
11. M.F. Drummond, M.J. Sculpher, G.W. Torrance Methods for the Economic Evaluation of Health Care Programmes (2nd ed.) 1997 Oxford University Press New York
12. Consumer Price Index http://global-rates.com/economic-indicators/ inflation/inflation.aspx 2011 [Accessed February 2, 2011]
13. Purchase Power Parity http://stats.oecd.org/Index.aspx?datasetcode=SNA- TABLE4 2011 [Accessed January 3, 2011]
14. G.Y. Locker, R. Mansel, D. Cella Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial Breast Cancer Res Treat 106 2007 229 238 (Pubitemid 350045007)
15. R. Mansel, G. Locker, L. Fallowfield Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial Br J Cancer 97 2007 152 161 (Pubitemid 47057463)
16. A. Rocchi, S. Verma Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Support Care Cancer 14 2006 917 927
17. T.E. Delea, K. El Ouagari, J. Karnon, O. Sofrygin Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective Breast Cancer Res Treat 108 2008 375 387 (Pubitemid 351431071)
18. T.E. Delea, J. Karnon, O. Sofrygin Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer Clin Breast Cancer 7 2007 608 618 (Pubitemid 47025818)
19. A.S. Coates, A. Keshaviah, B. Thurlimann Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 2007 486 492 (Pubitemid 350002953)
20. J. Wheler, M. Johnson, A. Seidman Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy Semin Oncol 33 2006 672 680 (Pubitemid 44828129)
21. S. Evers, M. Goossens, H. de Vet Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria Int J Technol Assess Health Care 21 2005 240 245 (Pubitemid 40656554)
22. N. van der Roer, M.E. Goossens, S.M. Evers, M.W. van Tulder What is the most cost-effective treatment for patients with low back pain? A systematic review Best Pract Res Clin Rheumatol 19 2005 671 684 (Pubitemid 40790494)
23. J. Soto Health economic evaluations using decision analytic modeling Principles and practicesutilization of a checklist to their development and appraisal Int J Technol Assess Health Care 18 2002 94 111 (Pubitemid 34408532)
24. M. Fonseca, G.T. Araujo, E.D. Saad Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil Rev Assoc Med Bras 55 2009 410 415
25. J.M. Gil, C. Rubio-Terres, A. Del Castillo Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer Clin Transl Oncol 8 2006 339 348
26. B.E. Hillner Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer Cancer 101 2004 1311 1322 (Pubitemid 39180386)
27. J. Karnon, T. Delea, V. Barghout Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective Eur J Health Econ 9 2008 171 183 (Pubitemid 351535306)
28. K. Moeremans, L. Annemans Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer Analysis based on the ATAC trial Int J Gynecol Cancer 16 Suppl. 2006 576 578 (Pubitemid 44410972)
29. C. Skedgel, D. Rayson, R. Dewar, T. Younis Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole Breast 16 2007 252 261 (Pubitemid 46796849)
30. C. Skedgel, D. Rayson, R. Dewar, T. Younis Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole Breast Cancer Res Treat 101 2007 325 333 (Pubitemid 46169887)
31. M.P. Lux, A. Wockel, A. Benedict Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system Onkologie 33 2010 155 166
32. M. Baum, A. Buzdar, J. Cuzick Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 2003 1802 1810 (Pubitemid 37310221)
33. R.C. Coombes, L.S. Kilburn, C.F. Snowdon Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 2007 559 570
34. B. Thurlimann, A. Keshaviah, A.S. Coates A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757 (Pubitemid 43016814)
35. J. Lundkvist, N. Wilking, S. Holmberg, L. Jonsson Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden Breast Cancer Res Treat 102 2007 289 299 (Pubitemid 46474838)
36. N.A. Risebrough, S. Verma, M. Trudeau, N. Mittmann Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer Cancer 110 2007 499 508 (Pubitemid 47106137)
37. D. Thompson, D.C. Taylor, E.L. Montoya Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer Value Health 10 2007 367 376 (Pubitemid 47485660)
38. S. Braun, T. Mittendorf, T. Menschik Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany Breast Care (Basel) 4 2009 389 396
39. T.E. Delea, J. Karnon, R.E. Smith Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer Am J Manag Care 12 2006 374 386 (Pubitemid 44063449)
40. K. El Ouagari, J. Karnon, T. Delea Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer Breast Cancer Res Treat 101 2007 37 49 (Pubitemid 47555323)
41. J. Karnon, T. Delea, S.R. Johnston Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective Pharmacoeconomics 24 2006 237 250 (Pubitemid 43374376)
42. P.E. Goss, J.N. Ingle, S. Martino A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 2003 1793 1802 (Pubitemid 37362955)
43. A. Howell, J. Cuzick, M. Baum Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
44. R.C. Chen, N.U. Lin, M. Golshan Internal mammary nodes in breast cancer: diagnosis and implications for patient management - a systematic review J Clin Oncol 26 2008 4981 4989
45. B. Fisher, J.H. Jeong, J. Bryant Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials Lancet 364 2004 858 868
46. J.F. Forbes, J. Cuzick, A. Buzdar Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 2008 45 53
47. P.E. Goss, J.N. Ingle, S. Martino Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA 17 J Clin Oncol 25 2007 2006 2011 (Pubitemid 46972784)
48. P.E. Lonning Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer Ann Oncol 17 2006 217 225 (Pubitemid 43160109)
49. BIG 1-98 Collaborative Group Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 2011 766 776
50. T. Saphner, D.C. Tormey, R. Gray Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 1996 2738 2746 (Pubitemid 26329660)
51. S. Jang, Y.K. Chae, T. Haddad, N.S. Majhail Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review Breast Cancer Res Treat 121 2010 273 279
52. M. Drummond, M. Barbieri, J. Cook Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report Value Health 12 2009 409 418
53. S. Boulenger, J. Nixon, M. Drummond Can economic evaluations be made more transferable? Eur J Health Econ 6 2005 334 346
54. R. Welte, T. Feenstra, H. Jager, R. Leidl A decision chart for assessing and improving the transferability of economic evaluation results between countries Pharmacoeconomics 22 2004 857 876 (Pubitemid 39273956)
55. Z. Philips, L. Bojke, M. Sculpher Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment Pharmacoeconomics 24 2006 355 371
56. F. Song, D.G. Altman, A.M. Glenny, J.J. Deeks Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses BMJ 326 2003 472
57. J.M. Robins, D.M. Finkelstein Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests Biometrics 56 2000 779 788
58. J.J. Caro, J. Moller, D. Getsios Discrete event simulation: the preferred technique for health economic evaluations? Value Health 13 2010 1056 1060